Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CXCR4 | P61073 | 14/20 | 0.74 |
| ▸ | EBP | Q15125 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614558 | 1.00 | MEN1 (1.00) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29373593 | 1.00 | MEN1 (1.00) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL7920925 | 0.98 | MEN1 (0.96) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL30545887 | 0.98 | MEN1 (0.96) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL7920921 | 0.98 | MEN1 (0.96) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL3675376 | 0.96 | MEN1 (0.93) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5322402 | 0.91 | MEN1 (0.84) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1966295 | 0.82 | MEN1 (0.70) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6072254 | 0.80 | CHRM2 (0.72) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25378299 | 0.78 | MEN1 (0.64) | MEN1TP53CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0841909-B1 | USE OF ALICYCLIC DIAMINES AS IMMUNOMODULATORS | NEOVACS (FR) | 2002-03-13 | — | — | EP | claimed |
| EP-2968347-B1 | MODULATORS OF THE EIF2ALPHA PATHWAY | UNIV CALIFORNIA (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11220477-B2 | Modulators of the eIF2alpha pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-11 | — | — | US | disclosed |
| US-10343981-B2 | Modulators of the eIF2alpha pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-09 | — | — | US | disclosed |
| US-20170342020-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-11-30 | — | — | US | disclosed |
| US-20170342020-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-11-30 | — | — | US | disclosed |
| US-9708247-B2 | Modulators of the eIF2alpha pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708247-B2 | Modulators of the eIF2alpha pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160096800-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-04-07 | — | — | US | disclosed |
| US-20160096800-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-04-07 | — | — | US | disclosed |
| US-9250249-B2 | Autophagy and phospholipidosis pathway assays | ENZO BIOCHEM, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9250249-B2 | Autophagy and phospholipidosis pathway assays | ENZO BIOCHEM, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| WO-2014144952-A2 | MODULATORS OF THE EIF2ALPHA PATHWAY | WALTER PETER (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011031330-A1 | AUTOPHAGY AND PHOSPHOLIPIDOSIS PATHWAY ASSAYS | ENZO LIFE SCIENCES, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20100093004-A1 | Autophagy and phospholipidosis pathway assays | ENZO LIFE SCIENCES, INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100093004-A1 | Autophagy and phospholipidosis pathway assays | ENZO LIFE SCIENCES, INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| WO-2010021681-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342020-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | EIF2AK1, EIF2A, EIF2AK3 | MEN1 4660/4885TP53 2707/4885CYP3A4 4804/4885 |
| US-11220477-B2 | Modulators of the eIF2alpha pathway | EIF2AK1, EIF2A, EIF2AK3 | MEN1 4660/4885TP53 2707/4885CYP3A4 4804/4885 |
| US-20160096800-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | EIF2AK1, EIF2A, EIF2AK3 | MEN1 4660/4885TP53 2707/4885CYP3A4 4804/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | MEN1 4176/4885TP53 796/4885CYP3A4 1741/4885 |
| US-10343981-B2 | Modulators of the eIF2alpha pathway | EIF2AK1, EIF2A, EIF2AK3 | MEN1 4660/4885TP53 2707/4885CYP3A4 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.